Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

Louis Letendre; Pierre Noel; William L. White; Ayalew Tefferi; Mark R. Litzow; Chin Yang Li; Georgene Schroeder

doi:10.1016/S0145-2126(99)00095-8

Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

Louis Letendre, Pierre Noel, William L. White, Ayalew Tefferi, Mark R. Litzow, Chin Yang Li, Georgene Schroeder

Research output: Contribution to journal › Article

6 Scopus citations

Abstract

Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m² daily) and subcutaneous AraC (10 mg/m²) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

Original language	English (US)
Pages (from-to)	811-815
Number of pages	5
Journal	Leukemia Research
Volume	23
Issue number	9
DOIs	https://doi.org/10.1016/S0145-2126(99)00095-8
State	Published - Sep 1 1999

Keywords

Chemotherapy
Leukemia
Myelodysplastic syndrome
Treatment

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S0145-2126(99)00095-8

Fingerprint Dive into the research topics of 'Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C'. Together they form a unique fingerprint.

Cite this

Letendre, L., Noel, P., White, W. L., Tefferi, A., Litzow, M. R., Li, C. Y., & Schroeder, G. (1999). Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leukemia Research, 23(9), 811-815. https://doi.org/10.1016/S0145-2126(99)00095-8

@article{863e69678d6c47f7ac3daaf7a4e1b30f,

title = "Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C",

abstract = "Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.",

keywords = "Chemotherapy, Leukemia, Myelodysplastic syndrome, Treatment",

author = "Louis Letendre and Pierre Noel and White, {William L.} and Ayalew Tefferi and Litzow, {Mark R.} and Li, {Chin Yang} and Georgene Schroeder",

year = "1999",

month = sep,

day = "1",

doi = "10.1016/S0145-2126(99)00095-8",

language = "English (US)",

volume = "23",

pages = "811--815",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

AU - Letendre, Louis

AU - Noel, Pierre

AU - White, William L.

AU - Tefferi, Ayalew

AU - Litzow, Mark R.

AU - Li, Chin Yang

AU - Schroeder, Georgene

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

AB - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

KW - Chemotherapy

KW - Leukemia

KW - Myelodysplastic syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032780477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032780477&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(99)00095-8

DO - 10.1016/S0145-2126(99)00095-8

M3 - Article

C2 - 10475620

AN - SCOPUS:0032780477

VL - 23

SP - 811

EP - 815

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -